237 related articles for article (PubMed ID: 16019657)
1. The contribution of Dr. Mary Walker towards myasthenia gravis and periodic paralysis whilst working in poor law hospitals in London.
Johnston JD
J Hist Neurosci; 2005 Jun; 14(2):121-37. PubMed ID: 16019657
[TBL] [Abstract][Full Text] [Related]
2. The Mary Walker effect: Mary Broadfoot Walker.
McCarter SJ; Burkholder DB; Klaas JP; Martinez-Thompson JM; Boes CJ
J R Coll Physicians Edinb; 2019 Sep; 49(3):255-259. PubMed ID: 31497797
[TBL] [Abstract][Full Text] [Related]
3. Contemporary opinions about Mary Walker: a shy pioneer of therapeutic neurology.
Keesey JC
Neurology; 1998 Nov; 51(5):1433-9. PubMed ID: 9818874
[TBL] [Abstract][Full Text] [Related]
4. Mary Broadfoot Walker (1888-1974): a historic discovery in myasthenia gravis.
Pearce JM
Eur Neurol; 2005; 53(1):51-3. PubMed ID: 15746548
[TBL] [Abstract][Full Text] [Related]
5. Mary Broadfoot Walker (1888-1974).
Johnston JD
J Neurol; 2007 Sep; 254(9):1306-7. PubMed ID: 18000738
[No Abstract] [Full Text] [Related]
6. Mary Broadfoot Walker: 83 years since a historical discovery.
Carvalho VM; Nogueira EAG; Rosa GR; Fragoso YD
Arq Neuropsiquiatr; 2017 Nov; 75(11):825-826. PubMed ID: 29236828
[TBL] [Abstract][Full Text] [Related]
7. The history of acetylcholinesterase inhibitors in the treatment of myasthenia gravis.
Katz NK; Barohn RJ
Neuropharmacology; 2021 Jan; 182():108303. PubMed ID: 32918950
[TBL] [Abstract][Full Text] [Related]
8. Dr Lazar Remen (1907-74): a forgotten pioneer in the treatment of myasthenia gravis.
Ohry A
J Med Biogr; 2009 May; 17(2):73-4. PubMed ID: 19401508
[TBL] [Abstract][Full Text] [Related]
9. Mary B. Walker, M.D. and the pioneering use of prostigmin to treat myasthenia gravis.
Keeney AH; Keeney VT
Doc Ophthalmol; 1997; 93(1-2):125-34. PubMed ID: 9476610
[TBL] [Abstract][Full Text] [Related]
10. [Opus posthumous].
Kotsias BA
Medicina (B Aires); 2017; 77(5):440-441. PubMed ID: 29044026
[No Abstract] [Full Text] [Related]
11. [Historical view on the development of knowledge about myasthenia gravis. (Introduction to a symposium)].
Hausmanowa-Petrusewicz I
Neurol Neurochir Pol; 1970; 4(3):261-4. PubMed ID: 4917026
[No Abstract] [Full Text] [Related]
12. A hypothesis to account for the Mary Walker phenomenon.
Patten BM
Ann Intern Med; 1975 Mar; 82(3):411-5. PubMed ID: 123143
[TBL] [Abstract][Full Text] [Related]
13. Breaking Down Myasthenic Crisis.
Wijdicks EFM
Neurocrit Care; 2020 Jun; 32(3):875-879. PubMed ID: 31981022
[No Abstract] [Full Text] [Related]
14. Mary Broadfoot Walker.
Lancet; 1974 Dec; 2(7893):1401-2. PubMed ID: 4143371
[No Abstract] [Full Text] [Related]
15. Treatment of myasthenia gravis.
Flacke W
N Engl J Med; 1973 Jan; 288(1):27-31. PubMed ID: 4347296
[No Abstract] [Full Text] [Related]
16. The miracle at St Alfege's: seventy years on.
Lee MR
J R Soc Med; 2007 Feb; 100(2):108-9. PubMed ID: 17277286
[No Abstract] [Full Text] [Related]
17. Henry R. Viets, MD, and the History of Myasthenia Gravis.
Feibel RM
Neurology; 2021 Feb; 96(7):322-326. PubMed ID: 33219137
[TBL] [Abstract][Full Text] [Related]
18. Some discoveries on myasthenia gravis: the background.
Walker MB
Br Med J; 1973 Apr; 2(5857):42-3. PubMed ID: 4572033
[No Abstract] [Full Text] [Related]
19. The history of myasthenia gravis.
Pascuzzi RM
Neurol Clin; 1994 May; 12(2):231-42. PubMed ID: 8041339
[TBL] [Abstract][Full Text] [Related]
20. Myasthenia gravis accompanied with hypokalemic periodic paralysis.
Sawanyawisuth K; Tiamkao S; Pratipanawatr T
J Med Assoc Thai; 2006 May; 89(5):727-9. PubMed ID: 16756062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
